

**Implementing core outcomes in kidney disease: report of the Standardized Outcomes in  
Nephrology (SONG) implementation workshop**

**Authors first and last names and highest degree:**

Allison Tong, PhD<sup>1,2</sup>, Braden Manns, PhD<sup>3</sup>, Angela Yee Moon Wang, MD<sup>4</sup>, Brenda Hemmelgarn, PhD<sup>3</sup>, David C Wheeler, MD<sup>5</sup>, John Gill, PhD<sup>6</sup>, Peter Tugwell, PhD<sup>7</sup>, Robert Pecoits-Filho, PhD<sup>8</sup>, Sally Crowe, PGDip<sup>9</sup>, Tess Harris<sup>10</sup>, Wim Van Biesen, PhD<sup>11</sup>, Wolfgang C Winkelmayr, MD, Sc.D<sup>12</sup>, Adeera Levin, MD<sup>6</sup>, Aliza Thompson, MD<sup>13</sup>, Vlado Perkovic, PhD<sup>14</sup>, Angela Ju, BPsych (Hons)<sup>1,2</sup>, Talia Gutman, MPH<sup>1,2</sup>, Amelie Bernier-Jean, MD<sup>1,2</sup>, Andrea Viecelli, MD<sup>15,16</sup>, Emma O'Lone MD<sup>1,2</sup>, Jenny Shen, MD<sup>17</sup>, Michelle A Josephson, MD<sup>18</sup>, Yeoungjee Cho, PhD<sup>15,16</sup>, Bénédicte Sautenet, PhD<sup>19</sup>, Marcello Tonelli, MD<sup>3</sup>, Jonathan C Craig, PhD<sup>20</sup> on behalf of the SONG Implementation Workshop Investigators\*

\*A complete list of SONG Implementation Workshop investigators is provided in the Acknowledgements section.

**Affiliations:**

<sup>1</sup>The University of Sydney School of Public Health, Sydney, NSW, Australia

<sup>2</sup>Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia

<sup>3</sup>Departments of Medicine and Community Health Sciences; Libin Cardiovascular Institute and O'Brien Institute of Public Health, University of Calgary, Calgary, Alberta, Canada

<sup>4</sup>Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong

<sup>5</sup>Centre for Nephrology, University College London, London, United Kingdom

<sup>6</sup>Division of Nephrology, University of British Columbia, Vancouver, BC, Canada

<sup>7</sup>Department of Medicine, University of Ottawa, Ottawa, Canada

<sup>8</sup>Department of Internal Medicine, School of Medicine, Pontifícia Universidade Católica do Paraná, Brazil

<sup>9</sup>Crowe Associates Ltd, London, United Kingdom

<sup>10</sup>PKD International, London, United Kingdom

<sup>11</sup>Renal Division, Ghent University Hospital, Ghent, Belgium

<sup>12</sup>Selzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, United States

<sup>13</sup>United States Food and Drug Administration, United States

<sup>14</sup>The George Institute for Global Health, Sydney, Australia

<sup>15</sup>Faculty of Medicine, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia

<sup>16</sup>Translational Research Institute, Brisbane, Australia

<sup>17</sup>Department of Nephrology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, United States

<sup>18</sup>Department of Medicine, The University of Chicago, Chicago, IL, United States

<sup>19</sup>Department of Nephrology Hypertension, dialysis, kidney transplantation, Tours Hospital, SPHERE – INSERM 1246, University of Tours and Nantes, Tours, France

<sup>20</sup>College of Medicine and Public Health, Flinders University, Adelaide, Australia

### **Corresponding author**

Allison Tong

Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead NSW 2145, Sydney, Australia

Tel: +61 2 9845 142 | Fax: +61 2 9845 1491 | Email: [allison.tong@sydney.edu.au](mailto:allison.tong@sydney.edu.au)

### **Sources of support:**

The workshop is funded by the National Health and Medical Research Council (NHMRC) (1098815). First author A.T. is supported by a NHMRC Fellowship (1106716). A.V. is supported by a NHMRC Medical Postgraduate Scholarship (1114539) and the Royal Australasian College of Physicians (Jacquot NHMRC Award for Excellence). A.B.J. is supported by a NHMRC Medical

Postgraduate Scholarship (1151246). J.S. is supported by a career development grant from the National Institute of Diabetes and Digestive Kidney Diseases at the National Institute of Health (K23DK103972). The funding organization had no role in the design and conduct of the study; collection; management, analysis and interpretation of the data; preparation, review, or approval of the manuscript.

**Running headline**

Implementation of core outcomes in kidney disease

## **ABSTRACT**

There are an estimated 14 000 randomized trials published in chronic kidney disease. The most frequently reported outcomes are biochemical endpoints, rather than clinical and patient-reported outcomes including cardiovascular disease, mortality, and quality of life. While many trials have focused on optimizing kidney health, the heterogeneity and uncertain relevance of outcomes reported across trials may limit their policy and practice impact. The international Standardized Outcomes in Nephrology (SONG) Initiative was formed to identify core outcomes that are critically important to patients and health professionals, to be reported consistently across trials. We convened a SONG Implementation Workshop to discuss the implementation of core outcomes. Eighty-two patients/caregivers and health professionals participated in plenary and breakout discussions. In this report, we summarize the findings of the workshop in two main themes: socializing the concept of core outcomes, and demonstrating feasibility and usability. We outline implementation strategies and pathways to be established through partnership with stakeholders, which may bolster acceptance and reporting of core outcomes in trials, and encourage their use by end-users such as guideline producers and policymakers to help improve patient-important outcomes.

### **Key words:**

Core outcome sets

Implementation

Kidney disease

Outcomes

Patient-centered care

Trials

## INTRODUCTION

To date, an estimated 14 000 randomized trials have been published in chronic kidney disease<sup>1</sup>.

Despite this substantive research effort and investment, patients with advanced CKD have mortality rates of up to 100 times higher than the general population<sup>2, 3</sup>, increased morbidity, and worse quality of life than patients with cancer and other chronic diseases<sup>4, 5</sup>. There remains an urgent need for rigorous, high-quality trials to address these poor outcomes, with greater attention given to the selection, measurement, and reporting of outcomes in trials, to maximize their practice and policy impact and thus their value<sup>6, 7</sup>.

The outcomes reported in trials are highly variable and measured in a plethora of ways, often without capturing those that are most meaningful for patients and clinicians for decision-making<sup>8</sup>.

In a recent analysis of 362 trials in hemodialysis, 81 different outcomes were reported using 10 700 different measures<sup>9</sup>. The five most frequently reported outcomes were all biochemical endpoints – phosphate, dialysis adequacy, anemia, inflammatory markers, and calcium<sup>9</sup>. Mortality and cardiovascular disease were reported in only 20% and 12% of trials, respectively. Fatigue, consistently identified by patients as a critically important outcome, even above mortality<sup>10-12</sup>, appeared in only 9% of trial reports<sup>9</sup>. Also, selectively reporting outcomes that favor the intervention or omitting outcomes such as adverse events may be misleading and can potentially cause harm<sup>13-15</sup>. A systematic review found that only two per cent of trials of immunosuppressive agents in kidney disease reported a quality of life outcome and almost all reported effect estimates that favored the intervention<sup>16</sup>.

These problems in outcome reporting have also been recognized in other medical specialties and disease areas, including cancer, cardiology, chronic pain, dementia, dermatology, hematology, and otitis media<sup>17-20</sup>, prompting efforts to establish core outcome sets to improve the relevance, certainty and efficiency of trial-based evidence to reliably inform decision-making. Core outcomes sets, as

defined by the Core Outcome Measures in Effectiveness Trials (COMET), are “an agreed standardised set of outcomes that should be reported, as a minimum, in all clinical trials in specific areas of health or healthcare”<sup>21</sup>. They may or may not be the primary outcome of trials, which are often selected because of their intervention-responsiveness and feasibility in terms of the resources required to achieve adequate statistical power. Core outcomes are identified through a consensus process to ensure they are critically important to patients and health professionals, with many initiatives drawing from the WHO-endorsed framework developed by the Outcome Measures in Rheumatology (OMERACT) group, which was formed 1992<sup>22-24</sup>.

While core outcomes have the potential to improve the consistency and relevance of outcomes in trials<sup>14, 25, 26</sup>, trialists have not consistently reported these outcomes when publishing results. The use of core outcomes has increased over time in trials in rheumatoid arthritis, whereas there has been limited change seen in other areas including gout and falls prevention<sup>25-32</sup>. Barriers to implementation by trialists may include lack of awareness about core outcomes among trialists, resource constraints, lack of incentives, and complexities in measuring patient-reported outcomes<sup>33, 34</sup>. Without consistent reporting of these core outcomes, there is little scope for end-users such as guideline producers and policymakers to capitalize on their potential benefits. However, little remains known about the perspectives of stakeholders on the use of core outcomes, and frameworks and interventions for the implementation of core outcomes are lacking<sup>35</sup>.

COMET recommends that core outcome developers prepare a dissemination and implementation plan to target potential users of core outcomes<sup>35</sup>. As part of the international Standardized Outcomes in Nephrology (SONG) Initiative, which was founded in 2014 to establish core outcomes across the spectrum of chronic kidney disease, we convened a workshop with patients, caregivers, and health professionals on the implementation of the core outcomes in trials in chronic kidney disease. The workshop also included specific reference to core outcome sets that had been established at the time of the workshop (Figure 1 Panels A and B) including for patients receiving

hemodialysis (fatigue, cardiovascular disease, vascular access function, mortality)<sup>9-12, 36-39</sup> and kidney transplant recipients (graft loss, cardiovascular disease, infection, life participation, cancer, mortality)<sup>40-43</sup>. These core outcome sets were developed using an evidence- and consensus-based process (systematic review, focus groups with nominal group technique, stakeholder interviews, an international Delphi Survey, and a consensus workshop) involving more than 1300 patients, caregivers, and health professionals from more than 70 countries in each stream (i.e. hemodialysis, kidney transplantation)<sup>10-12, 38, 39, 41, 42</sup>. The findings from the workshop will inform strategies and pathways for implementing core outcomes, with a focus on trials in nephrology.

## **SONG IMPLEMENTATION WORKSHOP**

### **Participants and contributors**

In total, 82 patients/caregivers/representatives from patient organizations (n=6), and health professionals (n=76) – including nephrologists, nursing and allied health professionals, researchers (including trialists), policy makers, and industry representatives – attended the workshop. Given the focus of the workshop on implementation of core outcomes, we invited patients/caregivers with experience in research or who held advocacy roles in consumer organizations (e.g. National Kidney Foundation, Patient-Centered Outcome Research Institute (PCORI) Home Dialyzors United, American Society of Nephrology /Kidney Health Initiative (ASN/KHI) Patient and Partnership Council, Polycystic Kidney Disease (PKD) International, PKD Foundation); and health professionals with leadership or advisory roles in professional societies (e.g. International Society of Nephrology, ASN, The Transplantation Society), funding agencies, research, regulatory, policy and industry organizations (including but not limited to: U.S. National Institutes of Health, U.S. Food and Drug Administration, U.S. Centers for Disease Control, U.S. Centers for Medicare and Medicaid services). Journal editors, trialists and epidemiologists, guideline developers, and those involved in renal registries and trial networks were also invited to attend. The investigators who

were unable to attend (n=84) contributed feedback on the workshop program and the draft workshop report by email.

### **Workshop program and materials**

The workshop was held on November 3<sup>rd</sup>, 2017 in New Orleans, United States, during the 2017 ASN Kidney Week. A pre-workshop survey and the workshop program and materials were sent to all investigators (n=160) prior to the workshop. The pre-workshop survey asked participants to: describe how they accessed and used (or plan to use) core outcomes (if applicable); suggest strategies/mechanisms/actions to promote the use of core outcomes; and describe/explain how they could support the implementation of core outcomes in their role. The initial responses (n=84) informed the questions and prompts for the workshop, while providing the participants with an opportunity to reflect on the topic in preparation for the breakout discussion groups.

The program is provided in Supplementary File 1 and was structured as follows: a presentation of the SONG Initiative to provide participants with an overview of the process; panel discussion reflecting the patient, professional society, industry, regulator, and trialist perspective; and breakout discussions on the opportunities, barriers and strategies for implementing core outcomes in chronic kidney disease. The attendees were pre-assigned to one of the eight breakout groups, which involved 10 to 12 diverse stakeholders (patients/caregivers, physicians, regulators, funders, industry, researchers) to prompt broader and dynamic discussions. Each group was moderated by a facilitator, who used a question guide. After the plenary session, the chairs (J.C., B.M.) asked each group to provide a brief summary.

All the presentations and break out group discussions were audiotaped and transcribed. The transcripts and survey responses were imported into HyperRESEARCH (ResearchWare Inc. Version 3.0) software for analysis. The first author (A.T.) coded the transcript line-by-line and

inductively identified concepts pertaining to the implementation of core outcomes. All participants were given two weeks to provide feedback on the draft workshop report and to confirm that the findings reflected the full range of their perspectives. Any additional comments were synthesized and included in the final report.

## **SUMMARY OF WORKSHOP DISCUSSION**

The participants' perspectives on implementing core outcomes in trials in kidney disease were summarized in two overarching themes: socializing the concept (to make the definition and purpose of core outcomes acceptable or considered the norm in the nephrology community) and demonstrating feasibility and usability, which are described in the following section. Selected quotations to support each theme are provided in Table 1. A schema depicting the themes is shown in Figure 2. Key strategies and recommendations for implementing core outcomes are outlined in Box 1.

### **Socializing the concept**

*“Socializing the concept, explaining to everybody why it’s important, making sure that all of our colleagues understand the advantage of why including core outcomes in clinical trials might actually help us get somewhere quite different in nephrology in a shorter period of time.”* (Health professional)

### ***Articulating a compelling case for change.***

The implementation of core outcomes requires efforts by the community (including professional and patient organizations) to convince health professionals and patients of the “advantages” of core outcomes – “half our colleagues don't even know they have to do clinical trials, let alone why we

need to do outcomes.” (Health professional) They urged that “unless there is some change, some improvement, then we’re stuck.” (Health professional) “Connecting the dots” for everyone would help them realize the lack of evidence about what is important to patients and clinicians – “we don’t have answers to questions because we’ve been mixed up, we don’t have the outcomes that everybody agrees to” (health professional) – and be persuaded of the pressing need for core outcomes.

Participants suggested emphasizing that a core outcome set “ensures consistency across studies, allows us to compare things so we have more knowledge, facilitates the uptake of results, reduces confusion, and ensures that we have relevance – to clinicians, patients, regulators, in a very real way.” (health professional) Trials would capture outcomes that have a direct impact on patients – “pain, infection, anxiety... all these things not included in trials,” and ultimately “accelerate quality research.” (patient) To have core outcomes available would “save” trialists from “thrashing about looking for an outcome because it’s been devised.” (health professional)

Core outcomes could identify “unforeseen consequences” of an intervention, even if there was “not a direct link to the intervention” and that this could be “leveraged.” Health professionals remarked: “we all get sort of strange and unexpected findings; unless you measure it, or report it, you don’t know.” (health professional) Also, it was noted that whilst an effect may not be seen in a single trial, consistent reporting of core outcomes would be important “because when you do a meta-analysis, perhaps you could get a positive result.” (health professional)

### ***Clarifying the intent and meaning***

Coherent communication about the definition and purpose of core outcomes was needed because the concept could be new and unfamiliar to some patients and health professionals. Researchers were concerned about the feasibility and relevance of using core outcomes as primary outcomes,

and that they may not be responsive to the study intervention. Thus, it was important to explain that core outcomes “need not be the primary outcome”, rather they were to be “collected and reported as part of that study even if they are not the primary outcome,” because they were critically important to stakeholders. They suggested to frame the use of core outcomes as an “add on” – i.e. “you come up with your own outcomes, that are nuanced towards your intervention, but then you add these extra [core] outcomes so you can at least say it made no difference to fatigue, cardiovascular disease as far as our trial is concerned.” (health professional) Also, to reiterate that core outcomes were included on the basis of their importance to patients and health professionals, irrespective of the intervention and the size and duration of the trial – “it’s about research to inform decision-making rather than the trialists finding something positive or responsive to their interventions.” (health professional)

### ***Ensuring trust and credibility***

Recognizing that the core outcomes were “internationally derived, used respected methodology, accredited, peer-reviewed, and non-commercial,” (patient) would promote trust and uptake. Researchers would need to have confidence in the consensus process, international and cross-cultural applicability, and reassurance that patients were involved in a meaningful and substantial way. There had to be consistency in the definition and interpretation of outcomes (and outcome measures), and validation and endorsement by relevant groups would strengthen credibility. Part of “selling core outcomes” entailed making transparent the rigor of the process, explaining “how did we get to here, who made these decisions, are they valid?” (health professional)

### ***Fostering community ownership***

Stakeholder groups (e.g. payers, regulators, industry, trialists and consumers) had to be engaged early and “buy in” to the process, to strengthen impetus for implementing core outcomes – “the big

danger is dissemination by lamination. It's got to come from the ground up. People have got to own the message.” (health professional) Participants suggested to “tailor the message to people, and to get the attention of patients through networks, and have patients tell the patients, we as the individual as well as our colleagues should own the message and distribute it from the ground up.” (health professional)

Health professionals recognized that conflicting agendas between stakeholder groups may be potential barriers to implementation – “pharmaceutical companies have agendas to bring drugs on the market as quickly as possible and to generate profits and sometimes we are not in agreement that the outcomes chosen are necessarily in alliance with what might be the priorities of patients and healthcare providers.” Further efforts were needed to “spread it [core outcomes] into [industry] organizations.” (health professional)

Participants posited that “competition” among researchers and societies could be a barrier to “accepting [the core outcomes] because they feel they weren't at the table.” (health professional) They thought it may be challenging to “get other groups (non-nephrology societies)” to agree on the harmonization of definitions for core outcomes and measures identified e.g. cardiovascular disease (cardiology) and agreed that “heavy hitters like oncology and cardiology needed to be on board and be in parallel doing similar things” (health professional) to gain broader acceptance and uptake.

### ***Modeling on exemplars of culture shift***

Highlighting prior successes of implementing similar or related initiatives in trials was identified as a strategy for promoting the uptake of this newer concept of ‘core outcomes. Participants referenced cardiology “where they had clear definitions of their key outcomes that they routinely use that have really helped to move the field forward.” (health professional) The requirements to register trials, obtain Institution Review Board approval, and report according to the Consolidated Standards of

Reporting Trials (CONSORT) were given as examples of “very significant brain shifts that have now been adopted very widely” (health professional) despite initial concerns of the added burden these would impose.

### ***Reinforcing with authoritative advisory support***

Mandating or insisting on the use of core outcomes in grant applications, journal publications, and regulatory approvals would force researchers “to toe the line” with efforts focused “further upstream” expected to be more effective. Trial registries (e.g. ClinicalTrials.gov) and funding agencies (e.g. NIH) would be the “stronger levers” for implementation because the use of core outcomes would be considered at the design phase of the trial. Trial registries could list the core outcomes to provide a “systematic way of making trialists think about it before they start the trial”. (health professional) Trial networks were also identified as a potential opportunity to provide trialists with guidance on using core outcomes. Explicit support from regulators (e.g. U.S. Food and Drug Administration, European Medicines Agency) would be a catalyst for implementation. Even if regulators “suggested” the use of core outcomes, sponsors would feel compelled to adopt them - “they will walk away with a strong message – ‘we have to do it, we can’t not do it.’” (health professional) There were concerns that mandating the use of core outcomes may be “too prescriptive” and that researchers could be encouraged rather than forced to use core outcomes; whereas others argued that “there must be not a carrot but a stick to implement it.”

### **Demonstrating feasibility and usability**

*“We don’t want them misused or used inappropriately, we want some tools for implementation.”*

### ***Providing proof of concept***

Empiric data to confirm that the “quality of studies improves after the implementation,” of core outcomes would “show that it’s not just a theoretical concept,” (health professional) and thus provide a strong reason for their use. Pilot testing core outcome sets in some trials was suggested. Another idea was to “go back to some trials, pharmaceutical trials through to some registry trials, to see what the effect would be if we have these core outcomes and test whether they work or not...to demonstrate benefit from having done this.” (health professional) For pragmatic trials, some health professionals suggested to evaluate “what would we have had to have done, what would the benefits be” if core outcomes were used.

### ***Readily accessible and visible***

Making core outcomes prominent by “publishing in journals, and also [presenting them] in workshops and educational activities” (health professional) would support uptake. Providing direct access to core outcomes (e.g. on the website) meant researchers could easily “download” the core outcome set when writing grant applications or trial protocols. The core outcomes and their respective measures had to be “readily available in different formats where it’s easy to pluck out from the web and use within your own structure of clinical trials.” (health professional) Participants suggested submitting core outcomes to relevant organizations such as the US National Quality Forum or the National Institutes of Health (NIH) Common Data Elements repository because researchers “go looking for measures – they go there and pull it off the shelf.” (health professional)

### ***Maximizing operationalizability***

Core outcomes require firmly established definitions and measures otherwise they would be too ambiguous to implement. For example, cardiovascular disease was a broad outcome domain (e.g. could include myocardial infarction, sudden cardiac death) and could be measured in multiple ways. A core outcome had to be stable over a reasonable time frame and be “definitive because the trials

we are doing now, another one is done in 10 years, 15 years, some of these outcomes change, of course mortality cannot change, before we call them core outcomes, we should have a very good crystal clear definition that doesn't change." (health professional) It was important to specify "how you ask the question, who delivers it."

Being able to integrate core outcomes into case report forms and "documented" in electronic health records and databases using classification codes, for example the International Classification of Disease (ICD) would facilitate efficient data collection on core outcomes in trials. "Micro-specification" of core outcomes would enable researchers to enter and extract data on core outcomes efficiently and in a reproducible way. This could be challenging for patient-reported outcomes such as fatigue – "to define them in a very granular way is absolutely excruciating." (health professional) Health professionals noted the increasing number of trials using quality-adjusted life years (QALYs) in cost-effectiveness analyses, and thus advocated that quality of life domains had to be "built in at the very beginning of study design."

Training researchers in how to use core outcome measures in trials would "speed up the implementation," and this could be delivered through tutorials and resources – "if there is a centralized way that you can go to the website to see how to administer the tool [e.g. paper versus electronic tablet], then you are more likely to have some standardization of measurement." (health professional) Systemic Lupus Erythematosus (SLE) was given as an example, where researchers had to be trained to assess and score disease activity using measures such as the SLE Disease Activity Index (SLEDAI) and British Isles Lupus Activity Group (BILAG) – "we all deliver it in the same way, and actually we all use the same program to analyze it so it does introduce uniformity." (health professional)

### ***Allowing adaptation when necessary***

Health professionals identified circumstances in which core outcomes could not be feasibly or appropriately implemented. Pragmatic or registry trials typically used “data that’s already being collected” as part of routine care or in registries, which may not currently include core outcomes and thus could not be feasibly included in such trials. An “opt out” approach could be considered whereby core outcomes would be “strongly encouraged and trialists would be expected to use them,” and researchers requested to provide a justification to seek exemption (e.g from funders, trial registration organizations) from using core outcomes. In grant applications, trialists could indicate if core outcomes have been included and if not to provide reason, similar to tick boxes used (e.g. to indicate whether the study had equal representation of genders, or IRB approval). However, they noted that “to come down really hard is going to be difficult but we are going to have flexibility in the appropriateness in the implementation of these, but then it’s very hard to call them ‘core.’” (health professional)

### ***Guaranteeing minimal burden, cost and consequence***

Health professional emphasized that core outcomes had to be “measured relatively easily, simply, and cheaply.” Imposing an undue “extra burden” to trials would be a barrier to implementation and “people would resent it.” In particular, trials “where you don’t have an a priori concern or it’s not your efficacy outcome, you don’t want to attach a lot of burden” in measuring the core outcomes. They cautioned that increased cost and resources to include core outcomes may potentially “inhibit the conduct of high quality trials, which would be counter to what we are trying to do.” Objections to the use of core outcomes were expected if they were seen as “a disincentive to running trials because it’s an extra bureaucratic layer they feel they have to jump through.” The resource implications of implementing core outcomes, particularly in low income countries, had to be considered.” Also, core outcomes should not “distract people, including the patients, from what the trial is about.”

Health professionals also recognized that in the current academic environment, “we are perpetuating research careers and science that is overdriven by biomarkers and surrogates, because they are a great track record, [you get] a lot of publications” and early career researchers in particular may not be able to invest the extra resources and time to measure and report core outcomes in their studies.

Incentives for implementing core outcomes had to be “non-punitive” such that providers or sponsors would not be “punished” based on their data pertaining to core outcomes. For example, with the increased use of extended criteria kidneys for transplantation, some health professionals observed that the commencement of dialysis post-transplant (due to delayed graft function) was sometimes deliberately delayed in order to achieve center-based performance indicators and targets. As a consequence, transplant recipients became volume overloaded for a longer period of time, which could lead to serious adverse effects. They remarked that health professionals may fear “that if core outcomes were going to get mandate, it’s going to be used against them, they will be called bad citizens” and urged that regulators (e.g. CMS) would have to guarantee that “negative or neutral results are not going to affect their registration.”

### ***Integrating into infrastructure***

Embedding core outcomes in registries, epidemiological cohort studies, and routine care (i.e. as quality indicators) would subsequently facilitate their uptake particularly in pragmatic trials “where we are trying to minimize the burden of data collection and use existing infrastructure.” Registries were somewhat “messy” with variable definitions and measures used for many outcomes including kidney function, which could be ascertained using different equations (e.g. MDRD, Cockcroft Gault). Health professionals suggested to “embed core outcomes in registries so that every six months patients are asked about fatigue, myocardial infarction, stroke, the data are all automatically recorded, its automatically in the electronic system.” (Health professional) Having core outcomes

embedded into routine clinical care could then be leveraged as part of clinical trials. Also, “if we can actually integrate these [core outcomes] into clinical care, it’s going to be easier for regulatory agencies to access them. If you collect it for post-market outcome assessment, it’s a lot easier for industry to collect if it’s something that’s captured as part of routine clinical care.”

## **DISCUSSION**

A multipronged approach to socialize the concept and demonstrate the feasibility and usability of core outcomes in nephrology studies could motivate trialists and facilitate the implementation of core outcomes in trials. This would involve advocating the need for improved consistency and relevance of research, and addressing potential skepticism by ensuring trust in the process of establishing core outcomes, buy-in from stakeholders, demonstrating the impact of similar initiatives, and securing support from authoritative bodies. The core outcomes should be readily accessible, clearly defined with validated measures, applicable, and of minimal burden to implement in trials internationally. Particularly for novel trial designs such as registry or pragmatic trials, core outcomes would need to be integrated into clinical care infrastructures or research registries.

Publishing core outcomes, communicating with relevant stakeholders groups, and involving potential users in the development process, have been identified by core outcome developers as strategies for dissemination and implementation<sup>35</sup>. Our workshop discussions indicate the need to make clear the goal and definition of core outcomes, framed in such a way that would be acceptable to researchers, and to address concerns about feasibility and applicability. Core outcomes are critically important to patients and clinicians for decision-making and should be considered for use as primary outcomes where possible, otherwise they should be added and tracked with primary outcomes that trialists have selected to be relevant to their intervention. In addition, core outcomes have potential benefits for other end-users such as guideline producers and policymakers.

Strategies to promote uptake of core outcomes can be conceptualized as “push” (directly encouraging trialists to collect and report data on core outcomes) or “pull” (encouraging end-users to highlight the need for these outcomes so that they can be used to benefit patients, such as in practice guidelines and/or quality measures). Likely both types of strategies will be required to effect meaningful change.

Partnerships with stakeholders and relevant organizations are needed to support and to expedite the uptake of core outcomes. COMET has identified trialists, trial registries, funders, research registries, journals, and systematic review organizations as having a role in the implementation of core outcomes<sup>35</sup>. In addition, participants in the workshop recognized that professional societies and consumers (i.e. patients, caregivers) could also help to educate and advocate for the use of core outcomes. Patient organizations liaise with clinicians, academic, industry, and government and regulatory agencies to promote research<sup>44</sup>. Patients and patient organizations also increasingly participate in guideline production, and thus are strongly positioned to support the implementation of core outcomes by appealing to both trialists and end-users.

There have been a few initiatives aimed at promoting the uptake of core outcomes in research proposals. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist recommends to use a common set of key outcomes in trials to “deter selective reporting of outcomes and to facilitate comparisons and pooling of results across trials in a meta-analysis.”<sup>45</sup> In the UK, the National Institute for Health Research guidance notes for applicants submitting a proposal for funding states that, “where established Core Outcomes exist they should be included amongst the list of outcomes unless there is good reason to do otherwise<sup>46</sup>,” and advises applicants to refer to the COMET database of core outcomes. Whilst there is currently no regulatory mandate specific to implementing core outcomes, regulators are seeking increased clarity about what outcomes matter to patients, that could be submitted for review and potential marketing approval,

and there have been initiatives to improve outcome reporting in trials. The US National Institutes of Health (NIH) recommends the use of common data elements in NIH-funded projects or registries<sup>47</sup>. The FDA and European Medicines Agency (EMA) have produced guidance documents on the use of patient-reported outcome measures in trials. The EMA and FDA can issue a qualification opinion on the acceptability of a specific use of a method (including outcome measures) for use in trials<sup>48, 49</sup>. These examples indicate that regulatory agencies or policy organizations have a potential role in supporting the implementation of core outcomes in trials.”

Despite these promising initial efforts, the potential benefits of adopting core outcomes do not appear to have been fully recognized by guideline producers or other end-users such as policymakers. Further efforts are needed to develop and evaluate training resources (e.g. tools, tutorials) to collect and report data on core outcomes, as well as educate trialists and end-users about their benefits for patients. Table 2 outlines implementation strategies and pathways covering education, dissemination, and resources and infrastructure for efficient operationalization of core outcomes, which may be established through partnership with stakeholders.

In summary, core outcome sets are being developed to improve the relevance, consistency, and reliability of trial evidence to inform decision-making and to systematically include the patient perspective. However, overcoming potential barriers to uptake necessitates partnerships with key stakeholders (including trialists and end-users) to “socialize” the concept of core outcomes and demonstrate that they can be feasibly applied in trials. Also, efforts will be needed to ensure ongoing monitoring and evaluation of the use and impact of core outcomes.

## **DISCLOSURE**

The authors have no relevant disclosures.

## REFERENCES

1. Cochrane Kidney and Transplant: Cochrane Kidney and Transplant Register; <http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register>. In (vol 2018), The Cochrane Collaboration, 2018
2. Robinson BM, Zhang J, Morgenstern H, *et al.* Worldwide, mortality risk is high soon after initiation of hemodialysis. *Kidney Int* 2014; **85**: 158-165.
3. de Jager DJ, Grootendorst DC, Jager KJ, *et al.* Cardiovascular and noncardiovascular mortality among patients starting dialysis. *J Am Med Assoc* 2009; **302**: 1782-1789.
4. Wyld M, Morton RL, Hayen A, *et al.* A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. *PLoS Med* 2012; **9**: e1001307.
5. Wong G, Howard K, Chapman J, *et al.* How do people with chronic kidney disease value cancer-related quality of life? *Nephrol* 2012; **17**: 32-41.
6. Moher D, Glasziou P, Chalmers I, *et al.* Increasing value and reducing waste in biomedical research: who's listening? *Lancet* 2016; **387**: 1573-1586.
7. Chalmers I, Bracken MB, Djulbegovic B, *et al.* How to increase value and reduce waste when research priorities are set. *Lancet* 2014; **383**: 156-165.

8. Baigent C, Herrington WG, Coresh J, *et al.* Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2017; **92**: 297-305.
9. Sautenet B, Tong A, Williams G, *et al.* Scope and consistency of outcomes reported in randomized trials conducted in adults receiving hemodialysis: a systematic review. *Am J Kidney Dis* 2018; doi: 10.1053/j.ajkd.2017.1011.1010.
10. Urquhart-Secord R, Craig JC, Hemmelgarn B, *et al.* Patient and caregiver priorities for outcomes in hemodialysis: an international nominal group technique study. *Am J Kidney Disease* 2016; doi: 10.1053/j.ajkd.2016.1002.1037.
11. Evangelidis N, Tong A, Manns B, *et al.* Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey. *Am J Kidney Disease* 2017; **70**: 464-475.
12. Tong A, Manns B, Hemmelgarn B, *et al.* Establishing core outcomes domains in hemodialysis: report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) consensus workshop. *Am J Kidney Disease* 2016; **69**: 97-107.
13. Saini P, Loke YK, Gamble C, *et al.* Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. *Br Med J* 2014; **349**: g6501.
14. Kirkham JJ, Dwan KM, Altman DG, *et al.* The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *Br Med J* 2010; **340**.

15. Mahady SE, Schlub T, Bero L, *et al.* Side effects are incompletely reported among systematic reviews in gastroenterology. *J Clin Epidemiol* 2015; **69**: 144053.
16. Howell M, Wong G, Turner RM, *et al.* The consistency and reporting of quality of life outcomes in trials of immunosuppressive agents in kidney transplantation: a systematic review and meta-analysis. *Am J Kidney Dis* 2016; **67**: 762-774.
17. Harman NL, Bruce IA, Callery P, *et al.* MOMENT--Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials* 2013; **14**: 70.
18. Iorio A, Skinner MW, Clearfield E, *et al.* Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. *Haemophilia* 2018; doi: 10.1111/hae.13504.
19. Grinich E, Schmitt J, Küster D, *et al.* Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. *Br J Dermatol* 2018; doi: 10.1111/bjd.16732.
20. Harding AJE, Morbey H, Ahmed F, *et al.* Developing a core outcome set for people living with dementia at home in their neighbourhoods and communities: study protocol for use in the evaluation of non-pharmacological community-based health and social care interventions. *Trials* 2018; **19**: 247.

21. Williamson PR, Altman DG, Bagley H, *et al.* The COMET Handbook: version 1.0. *Trials* 2017; **18**.
22. Boers M, Kirwan JR, Wells G, *et al.* Developing core outcome sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol* 2014; **67**: 745-753.
23. OMERACT. The OMERACT Handbook available at [http://www.omeract.org/pdf/OMERACT\\_Handbook.pdf](http://www.omeract.org/pdf/OMERACT_Handbook.pdf).
24. Tunis SR, Maxwell LJ, Graham ID, *et al.* Engaging stakeholders and promoting uptake of OMERACT core outcome instrument sets. *J Rheumatol* 2017; **Aug 1, 2017**: doi: 10.3899/jrheum.161273 (epub).
25. Kirkham JJ, BOers M, Tugwell P, *et al.* Outcome measures in rheumatoid arthritis. *Trials* 2013; **14**: 324.
26. Kirkham JJ, Clarke M, Williamson PR. A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. *Br Med J* 2017; **357**: j2262.

27. Bautista-Molano W, Navarro-Compán V, Landewé RB, *et al.* How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. *Clin Rheumatol* 2014; **33**: 1313-1322.
28. Araújo F, Cordeiro I, Ramiro S, *et al.* Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. *Rheumatol* 2015; **54**: 981-993.
29. Collins AJ, Foley R, Herzog C, *et al.* Excerpts from the United States Renal Data System 2007 annual data report. *Am J Kidney Disease* 2008; **51**: S1-320.
30. Copsey B, Hopewell S, Becker C, *et al.* Appraising the uptake and use of recommendations for a common outcome data set for clinical trials: a case study in fall injury prevention. *Trials* 2016; **17**: 131.
31. Lange T, Rataj E, Kopkow C, *et al.* Outcome assessment in total knee arthroplasty: a systematic review and critical appraisal. *J Athroplasty* 2017; **2017**: 2.
32. Mulla SM, Maqbool A, Sivananthan L, *et al.* Reporting of IMMPACT-recommended core outcome domains among trials assessing opioids for chronic non-cancer pain. *Pain* 2015; **156**: 1615-1619.
33. Boric K, Boric M, Dosenovic S, *et al.* Authors' lack of awareness and use of core outcome set on postoperative pain in children is hindering comparative effectiveness research. *J Comp Eff Res* 2018; **7**: 463-470.

34. Tong A, Crowe S, Gill JS, *et al.* Clinicians' and researchers' perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study. *BMJ Open* 2018; **8**: e021198.
35. Williamson PR, Altman DG, Bagley H, *et al.* The COMET Handbook: version 1.0. *Trials* 2017; **18**: 280.
36. Ju A, Unruh M, Davison S, *et al.* Establishing a core outcome measure for fatigue in patients on hemodialysis: a standardised outcomes in nephrology – hemodialiysis (SONG-HD) consensus workshop report. *Am J Kidney Dis* 2018; **72**: 104-112.
37. Ju A, Unruh M, Davison SN, *et al.* Patient-reported outcome measures for fatigue in patients on hemodialysis: a systematic review. *Am J Kidney Dis* 2018; **71**: 327-343.
38. Viecelli A, Tong A, O'Lone E, *et al.* Report of the standardized outcomes in nephrology – hemodialysis (SONG-HD) consensus workshop on establishing a core outcome measure for hemodialysis vascular access. . *Am J Kidney Dis* 2018; **71**: 690-700.
39. Viecelli AK, O'Lone E, Sautenet B, *et al.* Vascular access outcomes reported in maintenance hemodialysis trials: a systematic review. *Am J Kidney Dis* 2018; **71**: 382-391.

40. Sautenet B, Tong A, Chapman JR, *et al.* Range and consistency of outcomes reported in randomized trials conducted in kidney transplant recipients: a systematic review. *Transplantation* 2018; doi: 10.1097/TP.0000000000002278.
41. Tong A, Sautenet B, Poggio ED, *et al.* Establishing a core outcome measure for graft health: a standardized outcomes in nephrology - kidney transplantation (SONG-Tx) consensus workshop report. *Transplantation* 2018; doi: 10.1097/TP.0000000000002125.
42. Sautenet B, Tong A, Manera KE, *et al.* Developing a consensus-based priority outcome domains for trials in kidney transplantation: a multinational Delphi survey with patients, caregivers, and health professionals. *Transplantation* 2017; **101**: 1875-1886.
43. Tong A, Gill J, Budde K, *et al.* Toward establishing core outcome domains for trials in kidney transplantation: report of the standardized outcomes in nephrology - kidney transplantation consensus workshops. *Transplantation* 2017; **101**: 1887-1896.
44. Ingelfinger JR, Drazen JM. Patient organizations and research on rare diseases. *N Engl J Med* 2011; **364**: 1670-1671.
45. Chan AW, Tetzlaff JM, Gøtzsche PC, *et al.* SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *Br Med J* 2013; **346**: e7586.
46. NIHR: Supporting information for applications applying to the HTA programme. Health Technology Assessment Programme. National Institute for Health Research. (Available at

[https://www.nihr.ac.uk/funding-and-support/documents/HTA%20\\_Supporting%20Information.pdf](https://www.nihr.ac.uk/funding-and-support/documents/HTA%20_Supporting%20Information.pdf))

November 2017 In, 2017

47. NIH: NIH Common Data Element (CDE) Resource Portal available at [www.nlm.nih.gov/cde/](http://www.nlm.nih.gov/cde/) (Accessed 17th August 2018). In, Washington DC, United States, US National Library of Medicine, 2016

48. EMA: Qualification of novel methodologies for drug development: guidance to applicants available at [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2009/10/WC500004201.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004201.pdf) (Accessed 17th August 2018). In, London, UK, European Medicines Agency, 2014

49. FDA: Clinical Outcome Assessment Qualification Program available at <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284077.htm> (Accessed 22nd August 2018). In, Silver Spring, MD, United States, US Department of Health and Human Services, US Food and Drug Administration, 2018

## Acknowledgements

The following people attended the SONG Implementation workshop (New Orleans, 2017): SONG *Executive Committee* – Jonathan Craig, Angela Wang, Braden Manns, Tess Harris, Wolfgang Winkelmayr, Allison Tong, *Panelists* – Tess Harris, Adeera Levin, Stefano Stuard, Aliza Thompson, Vlado Perkovic, *Investigators* – Alexis Denny, Amelie Bernier-Jean, Andrea Viecelli, Andrew Davenport, Andrew Narva, Angela Ju, Arlene Chapman, Barbara Gillespie, Barbara Greco, Brigitte Schiller, Chuck Herzog, David Baron, David Johnson, David White, Denis Fouque, Edwina Brown, Elena Bavlovlencov, Elinor Mannon, Emma O’Lone, Fergus Caskey, Francesca Tentori\*, Frank Hurst, Germaine Wong, Gopala Rangan, Greg Germino, Gregorio Obrador, James Sloand, Jane Tan, Jeffrey Perl, Jenny Shen, Jonathan Fox, Kevan Polkinghorne, Krista Lentine, Krister Cromm, Lai-Seong Hooi, Laura James, Laura Dember, Li Zuo, Lionel Rostaing, Liz Lightstone, Lorraine Hamiwka, Mahesh Krishnan, Marinella Ruospo, Martin Wilkie, Meg Jardine, Michelle Josephson, Mike Rocco, Myra Kleinpeter, Nichole Jefferson, Nick Webb, Nieltje Gedney, Peter Kerr, Peter J Blankestijn, Rachel Perlman, Rainer Oberbauer, Rajnish Mehrotra, Ron Gansevoort, Ronald Perrone, Ronke Apata, Roslyn Mannon, Sara Davison, Sharon Teo, Stefano Stuard, Susan Furth, Talia Gutman, Tariq Sharif, Vanita Jassal, Vicente Torres, Vivekanand Jha, Will Herrington, Yeoungjee Cho, Yoonkyu Oh

**\*SONG Implementation Workshop Investigators**

First Name	Last Name	Primary Affiliation	Country
<b>SONG Executive Committee</b>			
Jonathan	Craig	The University of Sydney	Australia
Allison	Tong	The University of Sydney	Australia
Angela	Wang	The University of Hong Kong	Hong Kong
Brenda	Hemmelgarn	The University of Calgary	Canada
Braden	Manns	The University of Calgary	Canada
David	Wheeler	University College London	UK
John	Gill	University of British Columbia	Canada
Peter	Tugwell	University of Ottawa	Canada
Roberto	Pecoits-Filho	Pontificia Universidade Católica do Paraná	Brazil
Sally	Crowe	Crowe Associates Ltd	UK
Tess	Harris	PKD International	UK
Wim	van Biesen	Ghent University Hospital	Belgium
Wolfgang	Winkelmayer	Baylor College of Medicine	US
<b>Attendees and (non-attending) contributors</b>			
Adeera	Levin	University of British Columbia	Canada
Aditi	Sinha	All India Institute of Medical Sciences	India
Albert	Ong	University of Sheffield	UK
Alexis	Denny	PKD Foundation	US
Aliza	Thompson	U.S. Food and Drug Administration	US
Allison	Dart	University of Manitoba	Canada
Allison	Eddy	University of British Columbia	Canada
Amelie	Bernier-Jean	The University of Sydney	Australia
Amy	Kelly	The University of Sydney	Australia
Andrea	Viecelli	University of Queensland	Australia
Andrew	Davenport	The Royal Free London NHS Foundation Trust	UK
Andrew	Narva	U.S. National Institutes for Health	US
Angela	Ju	The University of Sydney	Australia
Ankit	Sharma	The University of Sydney	Australia
Anthony	Warrens	Queen Mary University of London	UK
Arlene	Chapman	University of Chicago	US
Armando	Teixeira-Pinto	The University of Sydney	Australia
Ayano	Kelly	Australian National University	Australia
Barbara	Murphy	The Mount Sinai Hospital	US
Benedicte	Sautenet	University of Tours	France
Benita	Padilla	National Kidney and Transplant Institute	Philippines
Bernard	Canaud	Fresenius Medical Care	France
Brian	Pullin	U.S. Food and Drug Administration	US
Brigitte	Schiller	Satellite Health	US
Bruce	Robinson	Arbor Research Collaborative for Health	US
Camilla	Hanson	The University of Sydney	Australia

Carmel	Hawley	University of Queensland	Australia
Charlotte	Logeman	The University of Sydney	Australia
Charmaine	Lok	University of Toronto	Canada
Christoph	Wanner	Universitätsklinikum Würzburg	Germany
Chuck	Herzog	Hennepin County Medical Center	US
Claudia	Rutherford	The University of Sydney	Australia
Curie	Ahn	Seoul National University Hospital	Korea
Daniel	Sumpton	The University of Sydney	Australia
David	Rosenbloom	ESRD Network 18	US
David	Harris	The University of Sydney	Australia
David	Baron	PKD Foundation	US
David	Johnson	University of Queensland	Australia
David	White	Patient representative	US
Debbie	Gipson	University of Michigan	US
Denis	Fouque	Université de Lyon	France
Denise	Eilers	Patient representative	US
Detlef	Bockenbauer	University College London	UK
Donal	O'Donoghue	Salford Royal NHS Foundation Trust	UK
Dongping	Chen	The Second Military Medical University	China
Dyke	Dunning	Patient	Australia
Edwina	Brown	Imperial College London	UK
Elena	Bavlovlencov	U.S Centers for Medicare & Medicaid Services	US
Elinor	Mannon	Georgia Regents University	US
Emilo	Poggio	Cleveland Clinic	US
Emma	O'Lone	The University of Sydney	Australia
Eric	Chemla	St George's University NHS Foundation Trust	UK
Fabienne	Dobbels	University of Leuven	Belgium
Faiez	Zannad	Université de Lorraine	France
Fergus	Caskey	University of Bristol	UK
Francesca	Tentori	DaVita	US
Frank	Hurst	U.S. Food and Drug Administration	US
Franz	Schaefer	University of Heidelberg	Germany
Germaine	Wong	University of Sydney	Australia
Gillian	Brunier	Sunnybrook Health Sciences Centre	Canada
Giovanni	Strippoli	University of Bari	Italy
Gopala	Rangan	University of Sydney	Australia
Greg	Knoll	University of Ottawa	Canada
Gregorio	Obrador	Universidad Panamericana, Campus México	Mexico
Harold	Feldman	University of Pennsylvania	US
Helen	Coolican	PKD Foundation of Australia	Australia
Hui-Kim	Yap	National University of Singapore	Singapore
Jaap	Groothoff	Emma Children's Hospital Academic Medical Centre	The Netherlands
James	Sloand	Baxter	US

Jane	Tan	Stanford University	US
Jayne	Locke	University of Alabama at Birmingham	US
Jeffrey	Perl	University of Toronto	Canada
Jenny	Shen	Harbor-UCLA Medical Center	US
Jeremy	Chapman	Westmead Hospital	Australia
Jie	Dong	Peking University	China
Jolanta	Malyszko	Medical University of Bialystok	Poland
Jonathan	Fox	University of Glasgow	UK
Juan	Dapueto	Univesridad de la Republica	Uruguay
Juliana	Tze-Wah Kao	National Taiwan University Hospital	Taiwan
Kai Ming	Chow	Chinese University of Hong Kong	Hong Kong
Karine	Manera	The University of Sydney	Australia
Karolis	Azukaitis	Vilnius University	Lithuania
Kevan	Polkinghorne	Monash University	Australia
Kevin	Fowler	Kidney Health Initiative	US
Kim Linh	Van	The University of Sydney	Australia
Klemens	Budde	Charité – Universitätsmedizin	Germany
Krista	Lentine	Saint Louis University	US
Krister	Cromm	Fresenius Medical Care	Germany
Lai-Seong	Hooi	Hospital Sultanah Aminah	Malaysia
Laura	James	The University of Sydney	Australia
Laura	Dember	University of Pennsylvania	US
Li	Zuo	Peking University People’s Hospital	China
Lionel	Rostaing	Toulouse University Hospital	France
Liz	Lightstone	Imperial College London	UK
Lorna	Marson	The University of Edinburgh	UK
Lorraine	Hamiwka	Unversity of Calgary	Canada
Mahesh	Krishnan	DaVita Kidney Care	US
Marcello	Tonelli	University of Calgary	Canada
Marinella	Ruospo	Diaverum, Medical Scientific Office	Italy
Mark	Unruh	University of New Mexico	US
Martin	Wilkie	NHS Sheffield Teaching Hospital	UK
Martin	Howell	The University of Sydney	US
Mary Amanda	Dew	University of Pittsburgh	US
Meg	Jardine	The George Institute for Global Health	Australia
Melissa	West	Kidney Health Initiative	US
Michael	Zappitelli	Montreal Children’s Hospital	Canada
Michael	Germain	Baystate Medical Center	US
Michelle	Josephson	The University of Chicago	US
Mike	Rocco	Wake Forest University	US
Myra	Kleinpeter	Tulane University	US
Nichole	Jefferson	Patient representative	US
Nick	Webb	The University of Manchester	UK
Nicole	Evangelidis	The University of Sydney	Australia

Nieltje	Gedney	Home Dialyzors United	US
Pam	Duquette	Johns Hopkins University	US
Peter	Kerr	Monash University	Australia
Patrick	Rossignol	University of Lorraine INI-CRCT	France
Peter	Reese	University of Pennsylvania	US
Peter J	Blankestijn	University Medical Center Utrecht	Netherlands
Prabir	Roy-Chaudhury	University of Arizona	US
Priti	Patel	U.S. Centers for Disease Control	US
Quinetta	Taylor	Patient	US
Rachel	Perlman	Arbor Research Collaborative for Health	US
Rainer	Oberbauer	University of Vienna	Austria
Rajnish	Mehrotra	University of Washington	US
Raymond	Vanholder	Ghent University	Belgium
Richard	Fluck	Derby Hospitals NHS Foundation Trust	UK
Richard	McGee	The Children's Hospital at Westmead	Australia
Rob	Quinn	University of Calgary	Canada
Robert	Lee	U.S. Food and Drug Administration	US
Ron	Gansevoort	University Medical Center Groningen	Netherlands
Ronald	Perrone	Tufts Medical Center	US
Ronke	Apata	U.S. Centers for Diseases Control	US
Roslyn	Mannon	University of Alabama at Birmingham	US
Sajeda	Youssef	The Royal London	UK
Sara	Davison	University of Alberta	Canada
Sarah	Bernays	The University of Sydney	Australia
Sarala	Naiker	Wits University	South Africa
Sharon	Teo	Royal Melbourne Hospital	Australia
Sheila	Jowsey-Gregoire	Mayo Clinic	US
Simon	Carter	The University of Sydney	Australia
Stefano	Stuard	Fresenius Medical Care	Germany
Stephen	Alexander	The Children's Hospital at Westmead	Australia
Stephen	McDonald	The University of Adelaide	Australia
Steve	Chadban	Royal Prince Alfred Hospital	Australia
Stuart	Goldstein	Cincinnati Children's Hospital Medical Center	US
Susan	Furth	University of Pennsylvania	US
Susan	Samuel	University of Calgary	Canada
Talia	Gutman	The University of Sydney	Australia
Tariq	Shafi	Johns Hopkins University	US
Tazeen	Jafar	Duke – National University Singapore	Singapore
Thomas	Hiemstra	University of Cambridge	UK
Tim	Pruett	University of Minnesota	US
Timmy	Lee	University of Alabama at Birmingham	US
Tushar	Vachharajani	Salisbury VA Health Care System	US
Vanita	Jassal	University of Toronto	Canada
Vera	Krane	Universitätsklinikum Würzburg	Germany

Vicente	Torres	Mayo Clinic	US
Vivekanand	Jha	George Institute for Global Health	India
Vlado	Perkovic	The George Institute for Global Health	Australia
Will	Herrington	Oxford University	UK
Yeoungjee	Cho	University of Queensland	Australia
Yoonkyu	Oh	Seoul National University Hospital	Korea
York	Pei	University of Toronto	Canada
Zeeshan	Butt	Northwestern University	US

Only includes investigators who have given permission to be a named contributor. USA, United States of America; UK, United Kingdom;

**Table 1. Selected quotations from the workshop discussions on the identification and implementation of core outcomes in hemodialysis**

Theme	Quotations	Group ID
<b>Socializing the concept</b>		
<b>Articulating a compelling case for change</b>	<p>This initiative is critical because its highlighted what is really important and help us prioritize where the unmet needs are and in general standardization and moving towards standardization is a good thing. (health professional)</p> <p>There's been a history of what we referred to initially as bad research and then later as inadequate research, or uninformed trials, and we need to shift culture to include these core outcomes. (health professional)</p> <p>We have a problem in nephrology because we don't have answers to questions, because we don't have outcomes that everybody agrees to, and we are trying to get the outcome right. (health professional)</p>	1,2,3,4,6,7,8
<b>Clarifying the intent and meaning</b>	<p>The intervention is not necessarily the important thing, the intervention is kind of by the by. You come up with your own outcomes, that are nuanced towards your intervention, but then you add these extra outcomes, you can at least say it made no difference to fatigue, as far as our trial is concerned, it made no difference to cardiovascular disease as far as our trial is concerned. (health professional)</p> <p>If you look at these, hemodialysis, there isn't a surrogate there, and if you look at the transplantation, there isn't a surrogate there because clinicians and patients basically uniformly de-prioritized them. We need to focus on that which is important, responsiveness in any given situation we can come back to, but it is what's important, and measured in a standard way. (health professional)</p> <p>Trialists want to find a positive outcome, from a clinician perspective and from a patient perspective they don't care whether their pain, or their graft is achieved with this, this, or that [intervention]. What's important to them is that it improves, so if we don't have the outcomes which are relevant, then its not addressing the things that matter to them. It's about research to inform decision-making rather than the trialist finding something that is positive or responsive to their interventions. (health professional)</p> <p>The sense from the patients was that they wanted to know the information even if it wasn't powered. (health professional)</p>	1,2,3,4,5,6,7,8
<b>Ensuring trust and credibility in the process</b>	<p>It includes patients, carers and clinician input, its international, it uses respected methodology, accredited, its on the COMET database, its peer reviewed, its non-commercial, so the advantage of that is that it delivers consistency, its comprehensive, reduced bias, and is trustworthy, which means that the benefits for me, the patient group, its real world. (patient)</p> <p>You have to overcome everyone's reluctance to use them, they don't understand the development, validity ... there's going to be a lot of advocacy needed, and a lot of trust in the methodology in the development for any one of these measures. (health professional)</p> <p>In order to be really accepted, make sure that the tools that are used are validated and are calibrated for the different populations in different countries, in different settings. (health professional)</p>	2,4,5,6,7,8
<b>Fostering community ownership</b>	<p>You have this problem of competition with non-nephrology societies, and there is sort of a 'this is my crossing over to my kind of territory'. I'm not sure how you are going to get other groups to agree, the harmonization of the definitions, that's a huge challenge, and we see that in KDIGO. (health professional)</p> <p>We've ignored the role of the payers which in many ways are more important than the regulators these days because they are the ones who make the decisions about whether the treatments are actually paid for and therefore used, so getting them on board is really important. (health professional)</p> <p>Before you disseminate you have to bring all the stakeholders together to put their approved on that if you will. Because there are many groups that will disseminate various measures and guidelines but you need to involve all the stakeholders, and government authorities, pharmaceutical companies, triallist. One potential way of doing that is once a group comes up with a set of guidelines and going out and going to these individuals and asking them to comment on it, what they see as good aspects as well as aspects that need to be tweaked. (health professional)</p> <p>The heavy hitters like oncology and cardiology need to be on board and need to be in parallel doing similar things. (health professional)</p>	1,3,4,5,7
<b>Referencing convincing</b>	<p>Look at the cardiovascular community where they for decades now, had clear definitions of their key outcomes that they routinely use that have really helped to move the field forward. (health professional)</p>	1,3,4,7,8

<b>examples of culture shift</b>	<p>Government agencies are now insisting you have open access trials, everybody is toeing the line, consumer engagement, that's all considered very important. Maybe having funders insist that these are part of the strategy to fund. They insist on trial registration, that's a burden but everyone does it it's a requirement. (health professional)</p> <p>The need to include things like CONSORT, these were very significant brain shifts that have now been adopted very widely. (health professional)</p> <p>If we can offer a powerful argument for, from a different field like cardiology or oncology, where a core outcome was developed and implemented, and how that was useful to, then this is definitely sellable. (health professional)</p> <p>A diabetes drug needs to have cardiovascular outcomes. That is also something which evolved over time. (health professional)</p>	
<b>Requiring authoritative support</b>	<p>And when we do have bodies within our societies that might be reviewing clinical protocols or clinical trials to see whether or not you can advocate for the use of them in those trials, think of us as professional advisors and consultants, and sort of engage some our society members in helping with the rolling out of core outcomes. (health professional)</p> <p>We [regulators] have opportunities when we meet with sponsors, we try to make sure that they are aware of other efforts that are going on that have bearing on their development programs so certainly that's an opportunity for us to share this important work and highlight the core outcomes that you've identified. (health professional)</p> <p>The funding agencies are actually the stronger lever rather than the journals, certainly the regulators for the trials that are relevant. (health professional)</p> <p>Trial registration might be a useful way of encouraging people to use these outcomes by listing it there and asking are you using these outcomes – that would be a systematic way of making trialists think about [core outcomes] before they start the trial. (health professional)</p> <p>This may be something that the journal editors may want to take on because if the journal editors say we recommend that we follow these outcomes, just as they now say you need to have a CONSORT diagram, you have to follow these core outcomes, or perhaps if you register in clinicaltrials.gov, you need to say that you are using those outcomes, that's a way that you could potentially promote this. (health professional)</p> <p>In some funding agencies, the program officer participates and oversees protocol development and that individual could insist on the use of standardized outcomes. (health professional)</p>	1,2,3,4,5,6,7,8
<b>Demonstrating feasibility and usability</b>		
<b>Providing proof of concept</b>	<p>There's going to be some skepticism, that these core outcome measures are going to work. I wonder if we could go back to some trials and just demonstrate within a number of different types of trials, some pharmaceutical trials through to some registry trials, what would be the effect if we have these core outcomes, and sort of test whether they do work or not. (health professional)</p> <p>If you can show that the quality of studies improves after the implementation of these core outcomes, that's a no brainer. (health professional)</p> <p>Maybe do pilot testing, if we come out with a first set of outcomes, let's do some pilot testing, a few different trials, small groups of patients, and prove to ourselves that what we chose makes sense. (health professional)</p>	1,4,5,6
<b>Accessible, applicable and practical</b>	<p>Have [core outcomes] readily available in different formats where its easy to pluck out the web and use within your own structure of your clinical trials so if its electronic that you could have a sort of an app or an iPad but you would also have the paper versions available, you would also have the various different formats available, for implementation of these outcomes. (health professional)</p> <p>If you are going to all the effort, of actually developing the tool, submit the measure to a measure organisation like the national quality forum. When people look for stuff, they actually go look there, the government goes looking there, others go looking there for measure, because its all validated so if you wanted to use you can pull it off the shelf. (health professional)</p>	1,2,3,4,5,6,7,8
<b>Maximizing operationalizability</b>	<p>They should be definitive because the trials that we do are done now, another one is done in 10 years, 15 years, some of these outcomes changes...before we call them core outcomes, we also have a very good crystal clear definition that doesn't change. (health professional)</p> <p>We almost all use CRFs now and its generated a code so whatever database you are going to be able to use, you could just use, 'here you are, here's our key core outcomes and if you are going to do this trial, if you said I've just got the code for you, here it is, it is easy. (health professional)</p>	1,2,3,4,5,6,7,8

	<p>Is there going to be some kind of tutorial or something? If there is a centralized way that you can go to the website of how to administer the tool, then you are more likely to have some standardization of measurement rather than saying, well measure this, this and this, how are you going to measure it, I ask my coordinators to do certain measurements, and they are going to do it 5 different ways unless I train them and say this is the way. (health professional)</p> <p>Create a micro specifications manual so if someone actually wanted to implement this, it would be done consistently. (health professional)</p> <p>You can have cardiovascular disease as your outcome but what exactly is your cardiovascular disease that you are talking about, so that granulatory. That is an issue for fatigue as well. So if people do report cardiovascular disease they are using the patients, ICD-9 codes, ICD-10 codes. (health professional)</p>	
<b>Allowing adaptation when necessary</b>	<p>We are moving to more efficient trial conduct where we are looking to use data that's already being collected as much as possible and in that situation there's no way we go back and redefine the outcomes, so we need to allow some flexibility in terms of how we use outcomes. (health professional)</p> <p>Are going to have to have flexibility in the appropriateness in the implementation of these, but then its very hard to call them core. (health professional)</p> <p>The core outcome measure should be flexible, and pragmatic enough, we have to allow some flexibility and leave it to some degree to the local practice, how to measure something, but it still has to be a standardized definition. (health professional)</p>	1,2,3,7
<b>Guaranteeing minimal burden, cost and consequence</b>	<p>If you're in a setting where you don't have a priori concern or its not your efficacy outcome, obviously you don't want to attach a lot of burden in trying to characterize these endpoints. (health professional)</p> <p>We are looking at trials that can be done around the world and the resources implications of what we are asking people to do in trials that may be for example run in low income countries with very limited resources, every additional thing that has to be collected has important cost and resource implications, that may inhibit the conduct of high quality trials which would be counter to what we are trying to do. (health professional)</p> <p>There's got to be some kind of non-punitive incentive ... how can regulators protect them from negative or neutral results [for the core outcomes], its not going to affect your registration? (health professional)</p> <p>The issue of cost, and cost not just in terms of financial terms, but cost in time with interaction with patients and the burden of implementing some measures and reporting data. (health professional)</p> <p>One challenge the tension between trying to be uniform across all trials and include this core set across all trials but not have it overwhelm the real goal of a particular trial...so it doesn't add so much burden to the trials and doesn't distract people, including the patients, from what the trial is about. (health professional)</p>	1,2,3,4,5,6,7
<b>Integrating into infrastructure</b>	<p>From a pragmatic trials perspective, we are trying to minimize the burden of data collection and use existing infrastructure. Another stakeholder are people in administrative registry type roles where it may not be readily apparent that these are outcomes that are necessarily relevant but certainly need to thought about prospectively in their implementation. A good example for me is the PDOPPS study, whatever information we learn from SONG-PD should be incorporated. (health professional)</p> <p>If we are trying to make trials simpler, just make the data collection simpler, to the extent that these things could get incorporated into routine clinical care, this task would be much easier. (health professional)</p> <p>If you come up with a set of care outcomes and they're a reasonably short list and they are very simple, that you could embed them in registries so that every 6 months patients are asked about fatigue, MI, stroke, the data is all automatically recorded, if it's a very small number, its automatically in the electronic system... the trials don't need to necessarily have to ask the patients the whole time, how do you feel fatigue, fill out our questionnaire, its done automatically by the nurses and you download it. (health professional)</p>	3,4,5,6,7

CONSORT, Consolidated Standards of Reporting Trials;

**Table 2. Implementation strategies and pathways through partnership with stakeholders**

Strategy / pathway	Professional societies	Consumers including consumer organizations	Trial networks / trialists	Research funders	Regulators/ policy makers	Trial registries	Administrative datasets /patient registries	Journals	Evidence synthesis groups (guidelines, systematic reviews)
<p>Educate about the need, definition, and purpose of core outcomes i.e. Core outcomes:</p> <ul style="list-style-type: none"> <li>Improve consistency and relevance of outcomes reported in trials</li> <li>Are identified through a systematic and transparent international consensus process</li> <li>Should be added to outcomes that trialists want to include in their trials (and does not have to be the primary outcome)</li> <li>Will have measures that are easy, simple, and inexpensive to use</li> <li>Need to be included on the basis of importance to patients and caregivers for decision-making (not based on expected response to the intervention)</li> </ul>	●	●	●					●	●
<p>Highlight examples of prior success in implementing related initiatives and impacts of core outcomes e.g.</p> <ul style="list-style-type: none"> <li>Implementation of reporting guidelines, trial registration</li> <li>Improved reporting of OMERACT core outcomes in rheumatoid arthritis</li> </ul>	●	●							
Provide training in the use of core outcomes (tools, resources, tutorials)	●	●	●						●
Demonstrate feasibility i.e. pilot test and evaluate use of core outcomes (including in pragmatic trials)			●						
Publish or provide a reference to core outcome sets	●	●	●	●	●	●		●	●
Recommend or mandate the use of core outcomes			●	●	●	●	●	●	●
Embed core outcomes into infrastructure (databases)					●		●		●

**Figure legends**

**Figure 1. SONG-HD (Panel A) and SONG-Tx (Panel B) Core Outcome Sets**

**Figure 2. Thematic schema**